Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8490899 | 0.87 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL442295 | 0.87 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL27745728 | 0.87 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL7173456 | 0.86 | ADORA3 (0.46) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL3148834 | 0.86 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL30822753 | 0.86 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL31392666 | 0.86 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL3501828 | 0.86 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL28874867 | 0.86 | ADORA3 (0.52) | ADORA3TK1HPGDPNPBLM | |
| SCHEMBL9489893 | 0.86 | ADORA3 (0.48) | ADORA3TK1HPGDPNPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| EP-0767842-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | claimed |
| JP-5273209-A | — | — | None | — | — | JP | disclosed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-12559748-B2 | Compositions and methods for the treatment of hemoglobinopathies | NOVARTIS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2025101722-A1 | HIGH-AFFINITY ENGINEERED CHROMODOMAINS | AXOIYA INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20030148513-A1 | Novel mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-08-07 | — | — | US | disclosed |
| WO-2003060085-A2 | MAMMALIAN NEURAL STEM CELLS, COMPOSITIONS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059276-A2 | NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002087503-A2 | COMPOSITIONS AND METHODS FOR TREATING COLORECTAL POLYPS AND CANCER | VANDERBILT UNIVERSITY (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-0767842-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000797-A1 | METHODS OF SCREENING FOR NUCLEOSIDE ANALOGS THAT ARE INCORPORATED BY HIV REVERSE TRANSCRIPTASE AND CAUSE INCORRECT BASE PAIRING | DARWIN MOLECULAR CORP (US) | 1996-01-11 | — | — | WO | disclosed |
| JP-H05273209-A | DNA DETECTING KIT | TAKARA SHUZO CO LTD | 1993-10-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | ADORA3 1197/4885TK1 472/4885HPGD 3333/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA3 4335/4885TK1 156/4885HPGD 3841/4885 |
| US-12559748-B2 | Compositions and methods for the treatment of hemoglobinopathies | HBZ, HBB, HBG1 | ADORA3 1966/4885TK1 528/4885HPGD 4879/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | ADORA3 2142/4885TK1 2068/4885HPGD 4791/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | ADORA3 77/4885TK1 884/4885HPGD 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.